Background: Patients with relapsed unresectable osteosarcoma represents an unmet need, so active and safe systemic treatments are required. Fas cell surface death receptor and mammalian target of rapamycin pathways are implicated in progressing osteosarcoma, and we had preclinical and clinical experience with a scheme that targets both pathways. Therefore, we designed a phase II trial with gemcitabine plus rapamycin, to determine the efficacy and safety, in this subset of patients.
Introduction
Osteosarcoma is the most frequent type of bone cancer, affecting 4.4, 1.7 and 4.2 cases for the 0-24, 25-59 and 60-85 age groups, respectively, per million of inhabitants and year [1] . Approximately, 78% of osteosarcoma patients present localized disease at diagnostic time [2] and 40% of these will have recurrence within 5 years [3] . Standard upfront treatment consists of combining chemotherapy with surgical excision. To date, highdose methotrexate, cisplatin and doxorubicin represent the most active agents for neoadjuvant and adjuvant treatment of osteosarcoma. After standard chemotherapy, the treatment of metastatic, relapsed or refractory osteosarcoma remains a challenge [4] . There are few trials that focus on second and further lines of chemotherapy [5] [6] [7] [8] [9] [10] . Current lines of investigation for advanced osteosarcoma focus on the apoptosis-mediating surface antigen [Fas cell surface death receptor (FAS)] and the mammalian target of rapamycin (mTOR) pathways [11] . FAS receptor and its ligand (FASL) are involved in the regulation of the tumorigenesis of primary malignancies and metastases. Administration of aerosol gemcitabine has been demonstrated to induce FAS expression and tumor regression in wild-type mice [12] and gemcitabine efficacy has been proved in a few case series of children and adolescents with recurrent osteosarcoma [7] . mTOR overexpression has been identified with higher disease progression rates and worse prognosis in osteosarcoma patients [13] . Phase I and II trials evaluating the efficacy of mTOR inhibitors in sarcomas have reported low rates of tumor response but progression-free survival rate (PFSR) at 4-months >20% [14, 15] . Our group has completed a phase I study for the combination of gemcitabine plus sirolimus in the treatment of advanced soft tissue sarcoma. Results have demonstrated that this combination presents mTOR signaling inhibition and antitumor activity in sarcoma models [16] . No clinical trial has been carried out to determine the efficacy of that combination as second-line for the treatment of osteosarcoma. The present single arm phase II trial was therefore designed to determine the efficacy and safety of gemcitabine plus sirolimus in advanced osteosarcoma.
Methods

Patients and study design
Patients with diagnosis of metastatic or unresectable high-grade osteosarcoma who had progressed after first-line standard chemotherapy were enrolled from 15 third-level hospitals. Inclusion and exclusion criteria are described in supplementary File S1, available at Annals of Oncology online. The main end point of this multicenter single-arm phase II trial was PFSR at 4 months and secondary end points included response rate, overall survival (OS), toxicity profile and correlation with biomarkers (ClinicalTrials.gov identifier NCT02429973). RECIST 1.1 was used for response evaluation. Sample size was estimated with optimal Simons two-stage design. For a error of 0.05 and power of 0.80, H0 of 20% and H1 of 40% were estimated for PFSR at 4 months. In the first stage 18 patients were to be enrolled, from which at least 4 patients should have PFS of longer than 4 months If this occurs, the study was to accrue additional 15 eligible patients for a total of 33 patients. Procedures were carried out in accordance with guidelines established by the hospital's Ethics Committee, as well as in conformance with the Declaration of Helsinki. This is an academic study sponsored by GEIS.
Patients received a maximum of six cycles of 3 weeks of the combination gemcitabine plus sirolimus. Recommended doses of gemcitabine (800 mg/m 2 ) and sirolimus (5 mg/day) were obtained from previous phase I trial [16] . Gemcitabine was administered intravenously at 10 mg/ m 2 /min rate on days 1 and 8 of each 21-day cycle. Gemcitabine dose reductions were planned according to drug brochure. Sirolimus was administered orally on a daily basis; except for the day before gemcitabine administration and on the same day of the infusion. Dose reduction was not allowed for sirolimus, since lower doses than 5 mg/day did not guarantee biologic effect according to pharmacodynamic analysis of the phase I trial [16] . Radiologic assessment was done every 2 months during the first year and then every 3 months. Central radiologic and pathologic reviews were planned. Adverse events were graded using the National Cancer Institute Common Toxicity Criteria version 3.0.
The statistical significance was established as P 0.05. All statistical procedures were carried out with SPSS 14.0 software. Kaplan-Meier estimations were used for time-to-event variables and the log-rank test was used to compare groups.
Translational procedures
The participants were blindly assessed by two expert pathologists in the field of sarcoma for both diagnostic confirmation and translational purposes. Phosphorylated mTOR (P-mTOR), Ribosomal Protein S6 (P-RPS6) and extracellular signal-regulated kinase (P-ERK1/2), and Ribonucleotide Reductase catalytic subunit M1 (RRM1) were selected for protein and mRNA expression, by immunohistochemistry and qRT-PCR, respectively. More detailed information on translational studies in supplementary File S1, available at Annals of Oncology online.
Results
From September 2012 to November 2014, 36 advanced osteosarcoma patients, progressing after standard chemotherapy, were assessed for eligibility. One patient was ineligible after central diagnosis of chondrosarcoma (supplementary Figure S1 , available at Annals of Oncology online). The clinical cut-off date for the final data analyses was 15 March 2016. At that time, 9 patients had completed 6 cycles, while 26 patients had an early discontinuation. From these latter, 17 discontinued due to progression, 6 due to toxicity and 3 stopped for other reasons (2 underwent surgery and one changed to other chemotherapy). The study continued to second stage after observing 9 progression-free cases at 4 months [8 stable disease (SD) and 1 PR] in the first 18 eligible patients (first stage).
A total of 116 treatment cycles were given to 35 enrolled patients, with a median of 3 cycles per patient (range 1-6). The median of dose intensity for gemcitabine was 85%, while for rapamycin it was 100%.
The median age was 24 years (3-60), with a predominance of males (60%). ECOG performance status was 0 in 32% of patients, 1 in 57% and 2 in 11%. The median follow-up was 11 months (3-33). A total of 60% of patients had received more than 1 previous chemotherapy line. Metastatic and unresectable locally advanced disease at baseline was present in 94% and 6%, respectively. The median of metastasis free interval, (from initial diagnosis to metastasis appearance), was 9 months and 37% of patients were metastatic at initial diagnosis. Other demographic and clinical characteristics at baseline are shown in Table 1 .
Median PFS was 2.3 months (95% CI 0-5.2 months) while PFS at 4, 6 and 12 months was 44% (95% CI 27% to 61%), 32% (95% CI 16% to 48%) and 6% (95% CI 0% to 15%), respectively. Median OS was 7.1 months (95% CI 2.8-11.4 months) and OS at 4, 6 and 12 months was 61% (95% CI 45% to 78%), 58% (95% CI 41% to 75%) and 29% (95% CI 13% to 45%), respectively ( Figure  1 ). There were 2 partial responses (PR) (6%) (supplementary Figure S2 , available at Annals of Oncology online) and 14 stabilizations (SD) (42%) from 33 assessable patients after central radiologic assessment. Two patients were not assessable for response: one patient suffered a bone fracture involving the target lesion after the first cycle and underwent surgery; in another case with bone metastasis, the whole tumor spread was considered as nonmeasurable lesions. Univariate analysis of clinical and pathologic factors showed PR/SD significantly correlated with better 4-month PFSR (P < 0.001) and OS (P < 0.001), whereas metastasis-free interval (P ¼ 0.043) was an additional significant prognostic factor for OS ( Table 2 ). All patients with SD were progression-free at 4 months. Patients with PR/SD had a median OS of 14.17 months (95% CI 7.63-20.68), while patients with progressive disease (PD) had 3.57 months (95% CI 2.18-4.95), respectively.
There were no toxic deaths, and the most frequent secondary side-effects, were: fatigue (60%), anemia (46%), neutropenia (43%), thrombocytopenia (34%) and mucositis (31%). Two heavily pretreated patients discontinued the treatment due to inadequate blood count-cell recovery, two due to G3/4 transaminitis, one in relation to G3/4 fatigue and one due to G2 pneumonitis. However in two cases of early discontinuation, PD was coincidentally reported (supplementary Table S1 , available at Annals of Oncology online). With regard to gemcitabine dose reductions and delays, in 11 out of 35 there was at least one delay, 11 out of 35 had at least one dose reduction along with some delay, and in two cases there were just dose reductions.
Protein expression analyses by immunostaining were fully assessable for all the biomarkers in 25 out of 35 cases (supplemen tary Figure S3 , available at Annals of Oncology online). Positive expression of RRM1 was significantly correlated with worse PFS and OS, whereas positive expression of P-ERK1/2 was correlated with a significant higher probability of OS (Figure 1 ) Protein expression of P-RPS6 and P-mTOR did not significantly correlate with clinical outcome (Table 3) . A multivariate analysis for OS has been carried out including those significant prognostic variables in the univariate analyses. Only RRM1 [HR 9.7 (1.95-48.2), P ¼ 0.005] and P-ERK1/2 [HR 3.1 (1.05-9.31), P ¼ 0.040] showed independent significance.
Analysis of mRNA expression did not show any significant correlation with clinical end points.
Discussion
About 35%-45% of patients with high grade localized osteosarcoma of extremities will eventually recur, with a median of relapse-free survival of 31 months. A relapse-free interval of longer than 2 years and good histologic response to neoadjuvant treatment at diagnostic time correlated significantly with better survival in recurrent osteosarcoma [17] . We confirm that metastasis-free interval had prognostic influence on OS and there was a trend toward worse OS in patients with poor histologic response to neoadjuvant treatment in our series. In the context of metastatic osteosarcoma, there is a clinical spectrum of patients: those with surgically resectable lung metastases constitute a significantly favorable population [3] . However, among those who are progressing after standard upfront chemotherapy and who are unsuitable for metastasectomy the prognosis is very poor. Systemic treatment has been demonstrated to significantly prolong survival even in this latter scenario [3] , but currently there is a limited number of schemes that could be considered active.
The 4-month PFSR of 44% attained in this trial situates the combination of gemcitabine plus sirolimus as a potentially active regimen in recurrent, unresectable osteosarcoma. This outcome is in line with other schemes considered to be active, such as high-dose ifosfamide which led to substantial activity measured as response rate (44%), but without reporting the PFS outcome. Nonetheless, this regimen was related to considerable toxicity [5] . Gemcitabine and docetaxel combinations showed activity in recurrent osteosarcoma with response rates ranging from 5% to 46% in two prospective [18, 19] and two retrospective studies [7, 19, 20] . At lower doses, gemcitabine 675/docetaxel 75 exhibited similar G3/4 myelotoxicity but lower activity (0% 4-month PFSR) than our study. However, at higher doses, gemcitabine 675-900/docetaxel 100-75, higher G3/4 myelotoxicity and similar activity were reported compared with our trial.
Besides, pemetrexed with 15% of PFS at 4 months in 32 patients [8] or trabectedin showing 3 out of 23 stabilizations were considered negative trials in this population [21] . Genetic aberrations of vascular endothelial growth factor and mTOR [22] , as well as inactivation or loss of p53 [23] and FAS [12] , are among the most relevant pathways that might be related to pathogenesis and progression of high-grade osteosarcoma, providing the basis for molecular targeted therapies. Thus, antiangiogenic agents such as sorafenib showed a 4-month PFS of 46% in a phase II trial [24] and pazopanib is being tested in an ongoing trial. In addition, sorafenib in combination with everolimus has been recently published showing a 4-month PFSR of 57% and a 6-month PFSR of 45% in a phase II trial [10] . The series of this latter study exhibited more favorable prognostic factors than our study.
The safety profile was manageable and consistent with the previous phase I [16] with hematologic toxicity being the most frequent grade 3-4 toxicity. Nevertheless, there were only 3 (9%) cases of febrile neutropenia. Overexpression of RRM1 has been consistently correlated with gemcitabine resistance in several epithelial tumors [25, 26] . Few retrospective or preclinical studies have focused on RRM1 expression in sarcoma, with conflicting results [27] and, to the best of our knowledge, none prospectively analyzed RRM1 as a potential predictive biomarker in sarcoma. All this being so, our trial showed a significant correlation between negative protein RRM1 expression and a better PFS and OS in recurrent osteosarcoma patients receiving this regime. It is worth highlighting that positive expression of P-ERK1/2 correlated significantly with better OS in our series. In this sense, recent research addresses the relevance of RAF/MEK/ERK pathway as a target in osteosarcoma [10, 28] .
Two important limitations of the study were, on one hand, patients could just receive six cycles at maximum due to budget constraints and, on the other hand, the fact that dose reductions were not allowed for sirolimus, which might explain early discontinuation cases due to toxicity in a small fraction of patients.
In conclusion, this trial met with prespecified assumptions for being considered active and could be a safer alternative of gemcitabine plus docetaxel.
The potential prognostic or predictive value of RRM1, P-ERK1/2 and pS6 deserves additional research as randomized trial comparing gemcitabine/docetaxel versus gemcitabine/sirolimus versus sorafenib/everolimus to cover the unmet needs in this osteosarcoma niche and to better understand the subset of patients that could be benefitted with a specific regime.
